Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Trial finds menopause breast cancer drug can trigger disease

  • Comment
A drug recommended as being a safe option for women going through the menopause women at risk of breast cancer is in fact more likely to trigger the disease, it has been revealed

Lancet Oncology reports that the risks are so great that a five-year trial by a team of Dutch researchers has had to be abandoned.

The synthetic steroid drug tibolone had previously been widely regarded as being safer than conventional hormone replacement therapy (HRT) among women at risk of breast cancer.

But it has now been shown to increase the chances of the cancer returning by 40%, of which 70% of the cases are aggressive tumours that are invariably fatal.

Tibolone is effective against menopause symptoms such as hot flushes, night sweats and bone loss, has been widely prescribed for women undergoing chemotherapy for the cancer.

The trial had assessed the effect of tibolone in more than 3,000 women who had undergone breast cancer surgery. A total of 237 (15.2%) of the women taking tibolone had a recurrence of cancer, compared with 165 (10.7%) of those prescribed a placebo.

More than 70% of the women were also undergoing adjuvant chemotherapy, but it is not clear how this might have affected the outcomes.

Study leader Professor Peter Kenemens, from the VU University Medical Centre in Amsterdam, said: 'There are insufficient data to establish the safety of tibolone in women who have had breast cancer and do not require or have finished adjuvant therapy.'

Lancet Oncology, 2009 10:2:135-146

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs